Alkem Laboratories to launch unique patented technology for treatment of Diabetic Foot Ulcer

12 Jan 2022 Evaluate

Alkem Laboratories (Alkem) has planned to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval.

This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

4923.30 21.80 (0.44%)
29-Apr-2024 14:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1524.45
Dr. Reddys Lab 6296.00
Cipla 1408.75
Zydus Lifesciences 959.45
Lupin 1639.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.